These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Lopaschuk GD, Barr R, Thomas PD, Dyck JR. Circ Res; 2003 Aug 08; 93(3):e33-7. PubMed ID: 12869392 [Abstract] [Full Text] [Related]
3. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. MacInnes A, Fairman DA, Binding P, Rhodes Ja, Wyatt MJ, Phelan A, Haddock PS, Karran EH. Circ Res; 2003 Aug 08; 93(3):e26-32. PubMed ID: 12869391 [Abstract] [Full Text] [Related]
4. The effects of chronic trimetazidine treatment on mechanical function and fatty acid oxidation in diabetic rat hearts. Onay-Besikci A, Guner S, Arioglu E, Ozakca I, Ozcelikay AT, Altan VM. Can J Physiol Pharmacol; 2007 May 08; 85(5):527-35. PubMed ID: 17632588 [Abstract] [Full Text] [Related]
6. Metabolic therapy for patients with diabetes mellitus and coronary artery disease. Rosano GM, Vitale C, Fragasso G. Am J Cardiol; 2006 Sep 04; 98(5A):14J-18J. PubMed ID: 16931201 [Abstract] [Full Text] [Related]
7. Influence of trimetazidine on myocardial injury in mice with diabetic cardiomyopathy. Zhao D, Ma J, Sun Y, Huang W, Fan J, Ye M, Hu B, Sun X. J Diabetes Complications; 2024 May 04; 38(5):108744. PubMed ID: 38613990 [Abstract] [Full Text] [Related]
10. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Fragasso G, Piatti Md PM, Monti L, Palloshi A, Setola E, Puccetti P, Calori G, Lopaschuk GD, Margonato A. Am Heart J; 2003 Nov 04; 146(5):E18. PubMed ID: 14597947 [Abstract] [Full Text] [Related]
11. Trimetazidine normalizes postischemic function of hypertrophied rat hearts. Saeedi R, Grist M, Wambolt RB, Bescond-Jacquet A, Lucien A, Allard MF. J Pharmacol Exp Ther; 2005 Jul 04; 314(1):446-54. PubMed ID: 15840766 [Abstract] [Full Text] [Related]
15. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Tuunanen H, Engblom E, Naum A, Någren K, Scheinin M, Hesse B, Juhani Airaksinen KE, Nuutila P, Iozzo P, Ukkonen H, Opie LH, Knuuti J. Circulation; 2008 Sep 16; 118(12):1250-8. PubMed ID: 18765391 [Abstract] [Full Text] [Related]
16. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy. Belardinelli R, Cianci G, Gigli M, Mazzanti M, Lacalaprice F. J Cardiovasc Pharmacol; 2008 Jun 16; 51(6):611-5. PubMed ID: 18574390 [Abstract] [Full Text] [Related]
17. [The effects of trimetazidine on left ventricular function and physical exercise tolerance in patients with ischemic cardiomyopathy]. Sisakian AS, Torgomian AL, Barkhudarian AL. Klin Med (Mosk); 2006 Jun 16; 84(10):55-8. PubMed ID: 17201276 [Abstract] [Full Text] [Related]